RTW Biotech Opportunities (LSE:RTW) Scaled Net Operating Assets: 1.12 (As of Dec. 2025)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
36 GF Score
Price $2.40
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Scaled Net Operating Assets?

RTW Biotech Opportunities LSE:RTW +3.00% 36 Scaled Net Operating Assets is 1.12 as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RTW Biotech Opportunities's operating assets for the quarter that ended in Dec. 2025 was $1,063.1 Mil. RTW Biotech Opportunities's operating liabilities for the quarter that ended in Dec. 2025 was $203.8 Mil. RTW Biotech Opportunities's Total Assets for the quarter that ended in Jun. 2025 was $766.1 Mil. Therefore, RTW Biotech Opportunities's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 1.12.

LSE:RTW
36GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RTW Biotech Opportunities's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(1063.056-203.819)/760.016
=1.13

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Balance Sheet Cash And Cash Equivalents
=1069.042 - 5.986
=1063.056

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=203.819 - 0 - 0
=203.819

RTW Biotech Opportunities's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(1063.056-203.819)/766.121
=1.12

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Balance Sheet Cash And Cash Equivalents
=1069.042 - 5.986
=1063.056

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=203.819 - 0 - 0
=203.819

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 1.12 mean?
RTW Biotech Opportunities (LSE:RTW) has a Scaled Net Operating Assets of 1.12 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Scaled Net Operating Assets too high?
RTW Biotech Opportunities' current Scaled Net Operating Assets is 1.12. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Scaled Net Operating Assets compare to BLK and BX?
RTW Biotech Opportunities' Scaled Net Operating Assets of 1.12 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for an Asset Management company?
A good Scaled Net Operating Assets depends on the Asset Management industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Scaled Net Operating Assets is 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Scaled Net Operating Assets of 1.12. The current Scaled Net Operating Assets is 1.12. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Scaled Net Operating Assets is 1.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score

Get the complete analysis for LSE:RTW

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price